Shopping Cart
Remove All
Your shopping cart is currently empty
Otlertuzumab (Synonyms: TRU-016)
Catalog No. T77358 Copy Product Info
🥰Excellent
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).
Otlertuzumab
Copy Product Info🥰Excellent
Catalog No. T77358
Synonyms TRU-016
Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM).
Otlertuzumab
Cas No. 1372645-37-8
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $215 | - | In Stock | |
| 5 mg | $560 | - | In Stock | |
| 10 mg | $896 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.5% (SDS-PAGE); 99.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM). |
| In vitro | Otlertuzumab (TRU-016), being developed by Trubion Pharmaceuticals Inc and Facet Biotech Corp, is an intravenously administered anti-CD37 IgG fusion protein for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), as well as autoimmune and inflammatory diseases. |
| Synonyms | TRU-016 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TSPAN26/CD37 |
| Molecular Weight | 144.65 kDa |
| Cas No. | 1372645-37-8 |
| Isotype | IgG1 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Otlertuzumab | purchase Otlertuzumab | Otlertuzumab cost | order Otlertuzumab | Otlertuzumab in vitro | Otlertuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.